EA200001169A1 - Специфично связывающиеся молекулы для сцинтиграфии, содержащие их конъюгаты и терапевтический способ лечения ангиогенеза - Google Patents

Специфично связывающиеся молекулы для сцинтиграфии, содержащие их конъюгаты и терапевтический способ лечения ангиогенеза

Info

Publication number
EA200001169A1
EA200001169A1 EA200001169A EA200001169A EA200001169A1 EA 200001169 A1 EA200001169 A1 EA 200001169A1 EA 200001169 A EA200001169 A EA 200001169A EA 200001169 A EA200001169 A EA 200001169A EA 200001169 A1 EA200001169 A1 EA 200001169A1
Authority
EA
Eurasian Patent Office
Prior art keywords
conjugates
antibodies
scintigraphy
therapeutic method
treating angiogenesis
Prior art date
Application number
EA200001169A
Other languages
English (en)
Other versions
EA005685B1 (ru
Inventor
Дарио Нери
Лоренцо ТАРЛИ
Франческа Вити
Манфред Бирхлер
Original Assignee
Айдгенессише Технише Хохшуле Цюрих
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/300,425 external-priority patent/US20030045681A1/en
Application filed by Айдгенессише Технише Хохшуле Цюрих filed Critical Айдгенессише Технише Хохшуле Цюрих
Publication of EA200001169A1 publication Critical patent/EA200001169A1/ru
Publication of EA005685B1 publication Critical patent/EA005685B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Abstract

Настоящее изобретение относится к антителам с субнаномолярной аффинностью, специфичным в отношении характерного эпитопа ED-B-домена фибронектина, маркера ангиогенеза. Оно относится также к применению меченных радиоактивным изотопом высокоаффинных анти-ED-B антител для обнаружения вновь образующихся кровеносных сосудов in vivo и к диагностическому набору, включающему указанное антитело. Оно относится также к конъюгатам, включающим указанные антитела и подходящие фотоактивные молекулы (например, разумно выбранный фотосенсибилизатор), и к их применению для избирательной опосредованной светом окклюзии новообразованных кровеносных сосудов.Отчет о международном поиске был опубликован 2000.03.16.
EA200001169A 1998-05-11 1999-05-11 Антитело, взаимодействующее с доменом ed-b (+) фибронектина, и способы его применения EA005685B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7533898A 1998-05-11 1998-05-11
US09/300,425 US20030045681A1 (en) 1998-05-11 1999-04-28 Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
PCT/EP1999/003210 WO1999058570A2 (en) 1998-05-11 1999-05-11 Antibodies to the ed-b domain of fibronectin, conjugates containing them and use therefor for diagnosis and therapy of tumors and diseases associated with angiogenesis

Publications (2)

Publication Number Publication Date
EA200001169A1 true EA200001169A1 (ru) 2001-04-23
EA005685B1 EA005685B1 (ru) 2005-04-28

Family

ID=26756726

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200001169A EA005685B1 (ru) 1998-05-11 1999-05-11 Антитело, взаимодействующее с доменом ed-b (+) фибронектина, и способы его применения

Country Status (24)

Country Link
US (1) US20070189963A1 (ru)
EP (1) EP1084145B1 (ru)
JP (1) JP2002514405A (ru)
CN (1) CN1250571C (ru)
AT (1) ATE301676T1 (ru)
AU (1) AU759207B2 (ru)
BR (1) BRPI9910394B8 (ru)
CA (1) CA2333833C (ru)
CZ (1) CZ300495B6 (ru)
DE (1) DE69926630T2 (ru)
DK (1) DK1084145T3 (ru)
EA (1) EA005685B1 (ru)
EE (1) EE05435B1 (ru)
ES (1) ES2247802T3 (ru)
HU (1) HU225675B1 (ru)
IL (1) IL139452A0 (ru)
IS (1) IS2522B (ru)
NO (1) NO327732B1 (ru)
NZ (1) NZ508600A (ru)
PL (1) PL199353B1 (ru)
SK (1) SK286822B6 (ru)
TR (1) TR200003317T2 (ru)
TW (1) TWI259837B (ru)
WO (1) WO1999058570A2 (ru)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
WO2000040262A1 (en) * 1999-01-05 2000-07-13 The Flinders University Of South Australia Novel agents and methods for treatment and diagnosis of ocular disorders
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DE19947559A1 (de) * 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
US6319273B1 (en) * 1999-12-16 2001-11-20 Light Sciences Corporation Illuminating device for treating eye disease
AU2001239470A1 (en) * 2000-02-24 2001-09-03 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
EP1259548A1 (en) * 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
SK2882003A3 (en) * 2000-09-07 2003-08-05 Schering Ag Receptor in the EDb fibronectin domain
DE10045803A1 (de) * 2000-09-07 2002-04-11 Schering Ag Rezeptor der EDb Fibronektin-Domäne
US20030100010A1 (en) * 2001-11-23 2003-05-29 George Jackowski Fibrinogen biopolymer Marker predictive of type II diabetes
EP1453546A2 (en) * 2001-12-04 2004-09-08 Nanospectra Biosciences, Inc. Treatment of angiogenesis disorders using targeted nanoparticles
DE60333820D1 (de) * 2002-01-03 2010-09-30 Bayer Schering Pharma Ag Konjugate mit einem für die ed-b-domäne von fibronectin spezifischen antikörper, und deren verwendung zum nachweis und zur behandlung von tumoren
MXPA04006517A (es) * 2002-01-03 2005-03-31 Schering Ag Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
CA2478414C (en) 2002-03-11 2012-11-13 Philogen S.P.A. Selective targeting of tumor vasculature using antibody molecules
ES2358730T3 (es) 2002-07-15 2011-05-13 Board Of Regents, The University Of Texas System Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer.
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
DE10348319A1 (de) * 2003-10-17 2005-05-19 Schering Ag Bindemoleküle für die Extra-Domäne B von Fibronectin zur Detektion von atherosklerotischen Plaques
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
WO2007056441A2 (en) * 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007054120A1 (de) * 2005-11-09 2007-05-18 Bayer Schering Pharma Aktiengesellschaft Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
EP1842553A1 (en) * 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
ATE548052T1 (de) 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
EP2100621A1 (en) 2008-03-10 2009-09-16 mivenion GmbH Polyether polyol dendron conjugates with effector molecules for biological targeting
JP2009244154A (ja) 2008-03-31 2009-10-22 Nationa Hospital Organization 老化、および血管障害を伴う疾患の検定のための組成物、キットおよび方法
EP2116555A1 (en) 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
WO2010056889A2 (en) * 2008-11-12 2010-05-20 The Trustees Of The University Of Pennsylvania Use of an antibody and a rare-earth based crystal
US20120301393A1 (en) 2009-12-14 2012-11-29 Scil Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain b of fibronectin
WO2011110490A1 (en) 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft Process for the production of radioactively labelled scfv antibody fragments, kits and compositions
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
WO2012172055A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
ES2657743T3 (es) 2011-07-19 2018-03-06 Philogen S.P.A. Terapia secuencial con anti-CTLA-4 e IL-2 dirigida
RU2481839C2 (ru) * 2011-08-16 2013-05-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет Министерства здравоохранения и социального развития" Способ лечения ишемической болезни сердца с дистальным или диффузным поражением коронарных артерий
EP2861616A1 (en) 2012-06-13 2015-04-22 Scil Proteins GmbH Human fusion proteins comprising single chain tnfalpha and targeting domains
WO2014094799A1 (en) 2012-12-19 2014-06-26 Scil-Proteins-Gmbh Ubiquitin moieties as a means for prolonging serum half-life
WO2014194784A1 (zh) * 2013-06-06 2014-12-11 合肥立方制药股份有限公司 人源抗纤连蛋白ed-b结构域的抗体及其用途
WO2016124702A1 (en) 2015-02-06 2016-08-11 Scil Proteins Gmbh Novel egfr binding proteins
PL3322721T3 (pl) 2015-07-16 2022-06-06 Navigo Proteins Gmbh Nowe białka wiążące immunoglobulinę i ich zastosowanie w oczyszczaniu na bazie powinowactwa
WO2017013136A1 (en) 2015-07-20 2017-01-26 Scil Proteins Gmbh Novel binding proteins based on di-ubiquitin muteins and methods for generation
WO2017084017A1 (zh) * 2015-11-16 2017-05-26 合肥立方制药股份有限公司 Ed-b蛋白在诊断组织增生中的应用
EP3452097A1 (en) 2016-05-04 2019-03-13 Navigo Proteins GmbH Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
KR102578256B1 (ko) 2016-08-11 2023-09-15 리플리겐 코포레이션 친화성 크로마토그래피를 위한 알칼리 안정 fc-결합 단백질
KR102338660B1 (ko) 2016-10-17 2021-12-10 화이자 인코포레이티드 항-edb 항체 및 항체-약물 접합체
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
EP3689903A4 (en) * 2017-09-30 2022-01-12 Hefei Lifeon Pharmaceutical Co. Ltd. FIBRONECTIN B DOMAIN BINDING PROTEIN
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
WO2020070150A1 (en) 2018-10-02 2020-04-09 Philogen S.P.A Il2 immunoconjugates
EP3660039A1 (en) 2018-11-30 2020-06-03 Philogen S.p.A. Il2 immunoconjugates
CA3221886A1 (en) 2021-06-23 2022-12-29 Cytune Pharma Interleukin-15 based immunocytokines
KR20240024241A (ko) 2021-06-23 2024-02-23 싸이튠 파마 인터루킨 15 변이체
WO2023131611A1 (en) 2022-01-04 2023-07-13 Philogen S.P.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor
WO2024028258A1 (en) 2022-08-01 2024-02-08 Philochem Ag Conjugates of psma-binding moieties with cytotoxic agents
WO2024047237A1 (en) 2022-09-01 2024-03-07 Philogen S.P.A. Tnf alpha and interleukin-2 combination therapy for non-melanoma skin cancer
WO2024052333A1 (en) 2022-09-06 2024-03-14 Philochem Ag Multivalent fibroblast activation protein ligands for targeted delivery applications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610967D0 (en) * 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods

Also Published As

Publication number Publication date
DK1084145T3 (da) 2005-12-19
AU759207B2 (en) 2003-04-10
SK286822B6 (sk) 2009-06-05
CA2333833A1 (en) 1999-11-18
NZ508600A (en) 2003-03-28
TR200003317T2 (tr) 2001-07-23
HUP0102992A3 (en) 2003-09-29
CZ300495B6 (cs) 2009-06-03
BRPI9910394A (pt) 2001-01-09
AU4039899A (en) 1999-11-29
EE200000802A (et) 2002-06-17
NO20005694D0 (no) 2000-11-10
DE69926630D1 (de) 2005-09-15
EP1084145B1 (en) 2005-08-10
BRPI9910394B1 (pt) 2013-07-02
CZ20004216A3 (en) 2001-05-16
WO1999058570A3 (en) 2000-03-16
CA2333833C (en) 2011-01-25
IS5708A (is) 2000-11-10
ATE301676T1 (de) 2005-08-15
ES2247802T3 (es) 2006-03-01
WO1999058570A2 (en) 1999-11-18
HUP0102992A2 (hu) 2001-11-28
PL199353B1 (pl) 2008-09-30
SK16792000A3 (sk) 2001-05-10
IS2522B (is) 2009-07-15
CN1303393A (zh) 2001-07-11
NO20005694L (no) 2001-01-10
NO327732B1 (no) 2009-09-14
JP2002514405A (ja) 2002-05-21
HU225675B1 (en) 2007-06-28
BRPI9910394B8 (pt) 2021-07-06
IL139452A0 (en) 2001-11-25
EP1084145A2 (en) 2001-03-21
CN1250571C (zh) 2006-04-12
EA005685B1 (ru) 2005-04-28
US20070189963A1 (en) 2007-08-16
DE69926630T2 (de) 2006-05-24
EE05435B1 (et) 2011-06-15
PL345845A1 (en) 2002-01-14
TWI259837B (en) 2006-08-11

Similar Documents

Publication Publication Date Title
EA200001169A1 (ru) Специфично связывающиеся молекулы для сцинтиграфии, содержащие их конъюгаты и терапевтический способ лечения ангиогенеза
US4416865A (en) Radiopharmaceuticals for localization of thromboembolic disease
JPS5813524A (ja) 血栓の位置決定用組成物
EA199800025A1 (ru) Стойкие реагенты для получения радиофармпрепаратов
JPH05500800A (ja) 蛋白質のテクネチウム／レニウム標識方法
ATE178053T1 (de) N2s2-chelatoren des hydrazino-typs
YU61701A (sh) Postupak i kit za efikasno radioobeležavanje proteina sa terapeutskim radioizotopom
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
DE69020007D1 (de) Vernetzte Antikörper und Verfahren zu ihrer Herstellung.
DE69937899D1 (de) Antikörper-serumprotein hybride
AR020071A1 (es) Anticuerpos que tienen una afinidad optimizada para un epitope caracteristico de dominio ed-b de la fibronectina, conjugados que contienen esos anticuerposy metodos terapeuticos para el tratamiento de la angiogenesis.
ATE296312T1 (de) Metalkomplexbildner
ATE160222T1 (de) Photoaktivierung von proteinen zu konjugationszwecken
DE69020182T2 (de) Vernetzte Antikörper und Verfahren zu ihrer Herstellung.
Keiser Immunological studies of the fragments of bovine cartilage proteoglycan produced by chondroitinase-trypsin digestion
JPH0283337A (ja) 癌診断薬及びそれを用いた腫瘍マーカーの回収方法
GB2314334A (en) Improved production of antibodies through the use of antigen antibody complexes
Tsuzuku et al. Preparative purification of lung-localizing rabbit anti-rat lung antibodies in vitro
BG105030A (en) Antibodies against ed-b domain of fibronectin, conjugates containing them, and their application for diagnostics and treatment of tumours and morbid conditions related to angiogenesis
Srivastava et al. Radiolabeled antiplatelet monoclonal antibodies for the scintigraphic localization of in-vivo thrombi and vascular lesions
ES2149155T3 (es) Peptidos sinteticos que contienen secuencias de factor viia y su utilizacion.
Riambau et al. Evaluation of Indium-111 Antifibrin Monoclonal Antibody Imaging in Deep Venous Thrombosis Diagnosis
JPS6169733A (ja) 静脈血栓症を証明するための放射線活性診断剤

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY

MK4A Patent expired

Designated state(s): RU